Clinical Commander

Back to dossier
cardio.cardiac-tamponade.uremic.v1PRODUCTION
cardio.cardiac-tamponade.uremic.v1

Cardiac tamponade — uremic pericardial effusion

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

9/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Uremic tamponade — intensified dialysis is FIRST-LINE; pericardiocentesis only for hemodynamic compromise OR effusion >250 mL not improving with HD (ESC 2015 §Uremic Pericarditis)

Inputs
1
Actions
0
Advance rule
Set
Advance when

uremic-context tamponade physiology suspected

Patient inputs (9)

Older ESRD patients have higher procedural risk + comorbidity burden (KDIGO 2024)

Compensatory tachycardia in tamponade physiology (ESC 2015)

HD vs PD vs not-yet-dialyzing; recent Kt/V; missed sessions — drives intensified-HD prescription (KDIGO 2024)

Definitive bedside dx — chamber collapse, IVC, swinging heart (ESC 2015 Class I); also assess effusion size (250 mL = drainage threshold per ESC 2015 §Uremic Pericarditis)

BUN >100 mg/dL strongly associated with uremic pericarditis (Banerjee AJKD 2014); response to HD tracked via BUN trend

Quantifies CKD stage; sCr trend during intensified HD reflects clearance adequacy (KDIGO 2024)

Hyperkalemia common pre-HD; affects HD prescription urgency (KDIGO 2024)

Uremic platelet dysfunction (qualitative defect) increases bleeding risk during pericardiocentesis even with normal count (Banerjee AJKD 2014)

Hypotension is part of Beck triad; ESRD patients often have baseline orthostasis from autonomic dysfunction (Banerjee AJKD 2014)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninghd_induced_hypotension_during_drainage_in_uremic_tamponade
    Hypotension during ultrafiltration in uremic tamponade pt — unmasking of borderline tamponade by HD-induced preload reduction (ESC 2015 §Uremic Pericarditis; Banerjee AJKD 2014)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninguremic_platelet_dysfunction_with_pericardial_bleeding_during_drainage
    Active pericardial bleeding during pericardiocentesis in ESRD pt with normal platelet count but qualitative dysfunction (Banerjee AJKD 2014)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_hyperkalemia_requiring_emergent_hd_with_tamponade_physiology
    K >6.5 + tamponade physiology — competing emergencies (KDIGO 2024)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverefibrinous_constrictive_pattern_post_uremic_pericarditis
    Persistent elevated RA pressure + dip-and-plateau pattern on RH cath after pericardial fluid resolution — fibrinous constrictive pericarditis from chronic uremic inflammation (ESC 2015 §Effusive-Constrictive)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereinadequate_hd_response_at_5_to_7_days_with_persistent_effusion
    Effusion not improving despite 5-7d intensified HD with adequate Kt/V — failure of first-line therapy (ESC 2015 §Uremic Pericarditis; Wood Am J Nephrol 1995)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Uremic pericardial effusion — intensified hemodialysis first-line; drainage second-line (ESC 2015 §Uremic Pericarditis; KDIGO 2024)
axis: uremic_pericardial_intensified_hd_first
Selected axis "Uremic pericardial effusion — intensified hemodialysis first-line; drainage second-line (ESC 2015 §Uremic Pericarditis; KDIGO 2024)" by default fallback (first axis)
  • normal saline
    first line
    isotonic_crystalloid
    250-500 mL bolus (CAUTIOUS — many ESRD pts have volume overload; assess fluid status first) • IV • small bolus then reassess
    triggers: hypotension_pre_drainage_with_volume_depletion
    Bridge preload — small volume only in volume-overloaded ESRD pt (ESC 2015; Banerjee AJKD 2014)
    rxcui 9863
  • norepinephrine
    rescue
    vasopressor
    0.05-0.1 µg/kg/min titrate to MAP ≥65 • IV • continuous
    triggers: SBP_lt_85_despite_fluids, HD_induced_hypotension_with_tamponade_unmasking
    Bridge only — does not address obstruction (Roy JAMA 2007); first choice in ESRD given fluid-overload concerns
    rxcui 7512
  • ddavp
    add on
    vasopressin_analog
    desmopressin 0.3 µg/kg IV pre-procedure • IV • single dose 30 min pre-pericardiocentesis
    triggers: uremic_platelet_dysfunction_pre_drainage
    Improves uremic platelet function via vWF release; standard pre-procedure prophylaxis in ESRD (Banerjee AJKD 2014)
    rxcui 3251
  • protamine
    rescue
    heparin_antagonist
    1 mg per 100 U residual heparin from prior HD session • IV • pre-procedure if recent HD with heparin
    triggers: recent_hd_with_systemic_heparin_pre_drainage
    Reverse residual heparin from HD prior to pericardiocentesis (ESC 2015; Banerjee AJKD 2014)
    rxcui 8825

outpatient playbook — drug actions (3)

  1. 1. maintenance HD per protocol
    Kt/V ≥1.4 per session × 3-4/wk • extracorporeal HD • TIW or per protocol
    trigger: ESRD
    KDIGO 2024
  2. 2. phosphate binder + cinacalcet
    rxcui 36567
    per PO4/PTH trend • PO • with meals
    trigger: CKD-MBD
    KDIGO 2024
  3. 3. ESA + iron supplementation
    rxcui 6011
    per Hb target 10-11.5 • SC/IV • TIW with HD
    trigger: Anemia of CKD
    KDIGO 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: ESRD on HD + missed sessions OR inadequate Kt/V + new dyspnea + JVD (ESC 2015 §Uremic Pericarditis); Pre-dialysis CKD stage 5 (eGFR <15) with pericardial friction rub or pleuritic chest pain (Banerjee AJKD 2014); Echo: pericardial effusion ± RV diastolic collapse / IVC plethora in dialysis patient (ESC 2015 Class I).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiac tamponade — uremic pericardial effusion** (cardio.cardiac-tamponade.uremic.v1).
Phenotype framing: Confirm uremic etiology via fluid analysis (typically hemorrhagic exudate; cell count, glucose, LDH, AFB, cytology to exclude malignant overlay; Sagristà-Sauleda EHJ 2002 PMID 12122206)
Scope: Uremic tamponade — intensified dialysis is FIRST-LINE; pericardiocentesis only for hemodynamic compromise OR effusion >250 mL not improving with HD (ESC 2015 §Uremic Pericarditis)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Uremic pericardial effusion — intensified hemodialysis first-line; drainage second-line (ESC 2015 §Uremic Pericarditis; KDIGO 2024)**.
1. normal saline 250-500 mL bolus (CAUTIOUS — many ESRD pts have volume overload; assess fluid status first) IV small bolus then reassess (isotonic_crystalloid, first line) — Bridge preload — small volume only in volume-overloaded ESRD pt (ESC 2015; Banerjee AJKD 2014)
2. norepinephrine 0.05-0.1 µg/kg/min titrate to MAP ≥65 IV continuous (vasopressor, rescue) — Bridge only — does not address obstruction (Roy JAMA 2007); first choice in ESRD given fluid-overload concerns
3. ddavp desmopressin 0.3 µg/kg IV pre-procedure IV single dose 30 min pre-pericardiocentesis (vasopressin_analog, add on) — Improves uremic platelet function via vWF release; standard pre-procedure prophylaxis in ESRD (Banerjee AJKD 2014)
4. protamine 1 mg per 100 U residual heparin from prior HD session IV pre-procedure if recent HD with heparin (heparin_antagonist, rescue) — Reverse residual heparin from HD prior to pericardiocentesis (ESC 2015; Banerjee AJKD 2014)

Setting playbook (outpatient) — Long-term surveillance for uremic pericarditis recurrence + dialysis adequacy maintenance + transplant pathway if eligible (KDIGO 2024; ESC 2015 §Long-term Follow-up)
5. maintenance HD per protocol Kt/V ≥1.4 per session × 3-4/wk extracorporeal HD TIW or per protocol — ESRD (KDIGO 2024)
6. phosphate binder + cinacalcet per PO4/PTH trend PO with meals — CKD-MBD (KDIGO 2024)
7. ESA + iron supplementation per Hb target 10-11.5 SC/IV TIW with HD — Anemia of CKD (KDIGO 2024)

Non-pharmacologic actions:
- Quarterly nephrology + annual cardiology visits
- Transplant team active follow-up if listed
- Dietitian consult quarterly
- Patient + family education ongoing for adherence

AVOID / contraindication checks:
- Positive_pressure_ventilation_AVOID_pre_drain (ESC 2015)
- NSAIDs_AVOID_uremic_platelet_dysfunction_AKI_progression (ESC 2015 §Uremic Pericarditis)
- Colchicine_HOLD_egfr_lt_30 (drug label; ESC 2015 — no proven benefit in uremic anyway)
- Colchicine_dose_reduce_egfr_30_60_to_0.3_mg_daily (drug label; minimal evidence supporting use in uremic etiology)
- Steroids_LIMITED_benefit_only_for_refractory_or_autoimmune_overlay (ESC 2015)
- Systemic_heparin_AVOID_during_HD_if_pericardial_bleeding_risk_use_regional_citrate_or_heparin_free (KDIGO 2024)
- Large_volume_fluid_resuscitation_AVOID_volume_overload_in_esrd (Banerjee AJKD 2014)

Monitoring

Regimen monitoring:
- continuous ECG during drainage (ESC 2015)
- art line BP pre and post (Adler 2015)
- echo post drain immediate then q24h x 7d then weekly (re-accumulation common in uremic if HD inadequate)
- BUN Cr K pre and post each HD (KDIGO 2024 — track clearance adequacy)
- fluid analysis cell count glucose LDH AFB cytology culture (Sagristà-Sauleda PMID 12122206)
- CRP q48h during HD intensification (resolution tracks with uremic clearance)
- platelet function assessment if bleeding concerns (Banerjee AJKD 2014)

Setting (outpatient) monitoring:
- Quarterly echo for first year post-tamponade then annually
- Monthly BMP
- Quarterly Kt/V

Monitoring phase: Re-accumulation surveillance (echo q24h × 7d then weekly), BUN/Cr trend during intensified HD, CRP trend, fluid analysis follow-up (ESC 2015 §Follow-up)

Disposition

Current setting: outpatient — Long-term surveillance for uremic pericarditis recurrence + dialysis adequacy maintenance + transplant pathway if eligible (KDIGO 2024; ESC 2015 §Long-term Follow-up)

Disposition criteria:
- Long-term continuation under multidisciplinary team; transition to transplant cardiology if transplanted

Escalation triggers (move to higher acuity):
- Recurrent uremic pericarditis → re-intensify HD + cardiology re-evaluation
- Vascular access loss → vascular surgery emergent
- Transplant offer → transplant team coordination

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Hypotension during ultrafiltration in uremic tamponade pt — unmasking of borderline tamponade by HD-induced preload reduction (ESC 2015 §Uremic Pericarditis; Banerjee AJKD 2014)
- [LIFE_THREATENING] Active pericardial bleeding during pericardiocentesis in ESRD pt with normal platelet count but qualitative dysfunction (Banerjee AJKD 2014)
- [LIFE_THREATENING] K >6.5 + tamponade physiology — competing emergencies (KDIGO 2024)

Citations

- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Uremic Pericarditis — remains current as of 2026-05-14. KDIGO 2024 ESRD/dialysis management + Banerjee AJKD 2014 uremic pericarditis modern review anchor uremic-specific intensified HD + drainage threshold + platelet dysfunction prophylaxis. [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 17456823) [PMID:17456823](https://pubmed.ncbi.nlm.nih.gov/17456823/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)
- Cited evidence (PMID 12122206) [PMID:12122206](https://pubmed.ncbi.nlm.nih.gov/12122206/)
- Cited evidence (PMID 23992557) [PMID:23992557](https://pubmed.ncbi.nlm.nih.gov/23992557/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2015 ESC Guidelines for the diagnosis and management of pericardial diseases (Adler EHJ 2015 PMID 26320112) §Uremic Pericarditis — remains current as of 2026-05-14. KDIGO 2024 ESRD/dialysis management + Banerjee AJKD 2014 uremic pericarditis modern review anchor uremic-specific intensified HD + drainage threshold + platelet dysfunction prophylaxis. — PMID:26320112
  • Cited evidence (PMID 17456823) — PMID:17456823
  • Cited evidence (PMID 20656240) — PMID:20656240
  • Cited evidence (PMID 12122206) — PMID:12122206
  • Cited evidence (PMID 23992557) — PMID:23992557